Cited by 424Cardiac Fibrosis and RemodelingCardiomyopathy and Myosin StudiesSingle-cell and spatial transcriptomics

Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy

Open access
Chaffin, Mark, Papangeli, Irinna, Simonson, Bridget, Akkad, Amer-Denis, Hill, Matthew C., Arduini, Alessandro, Fleming, Stephen J., Melanson, Michelle +11 more·2022·Nature

Abstract

Heart failure encompasses a heterogeneous set of clinical features that converge on impaired cardiac contractile function 1,2 and presents a growing public health concern. Previous work has highlighted changes in both transcription and protein expression in failing hearts 3,4, but may overlook molecular changes in less prevalent cell types. Here we identify extensive molecular alterations in failing hearts at single-cell resolution by performing single-nucleus RNA sequencing of nearly 600,000 nuclei in left ventricle samples from 11 hearts with dilated cardiomyopathy and 15 hearts with hypertrophic cardiomyopathy as well as 16 non-failing hearts. The transcriptional profiles of dilated or hypertrophic cardiomyopathy hearts broadly converged at the tissue and cell-type level. Further, a subset of hearts from patients with cardiomyopathy harbour a unique population of activated fibroblasts that is almost entirely absent from non-failing samples. We performed a CRISPR-knockout screen in primary human cardiac fibroblasts to evaluate this fibrotic cell state transition; knockout of genes associated with fibroblast transition resulted in a reduction of myofibroblast cell-state transition upon TGFβ1 stimulation for a subset of genes. Our results provide insights into the transcriptional diversity of the human heart in health and disease as well as new potential therapeutic targets and biomarkers for heart failure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04817-8

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Existing snRNA-seq and scRNA-seq studies did not identify human cardiac fibroblast populations that drive fibrosis.

    “However, they did not identify human cardiac fibroblast populations that drive fibrosis.”

    From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [20]

    The ‘Activated fibroblasts in DCM and HCM’ section reports that the study identified a distinct activated cardiac fibroblast population nearly exclusive to cardiomyopathy patients, contrary to the claim that it did not identify such a population. The ‘Cardiac fibrosis assay’ section also tests genes from that population’s activation trajectory for effects on myofibroblast formation. These findings do not establish that the population drives fibrosis in patients, but they contradict the claim’s categorical statement that no relevant population was identified. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Existing snRNA-seq studies of the human heart rely on nuclear RNA and lack cellular transcriptomic, epigenetic and proteomic profiling needed for a granular picture of immune and fibroblast populations in the failing heart.

    “However, these studies rely on nuclear RNA information and lack cellular transcriptomic, epigenetic and proteomic profiling information necessary to obtain a granular picture of the precise immune and fibroblast populations that emerge in the failing human heart and collaborate to drive cardiac fibrosis.”

    From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [19]

    The Methods describe single-nucleus RNA sequencing, supporting the claim that this study relies on nuclear RNA rather than integrated cellular transcriptomic, epigenetic and proteomic profiling. But the ‘Changes in cell sub-populations’ and ‘Activated fibroblasts in DCM and HCM’ sections identify macrophage sub-populations and a disease-associated activated fibroblast population. The paper therefore does not support the implication that its approach cannot provide a granular picture of those populations, or establish that the additional profiling is necessary to do so. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated conditions.

    “By contrast, cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ (refs. 19,39,40), IL-1β (ref. 41)) conditions.”

    From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [19]

    The Cardiac fibrosis assay and Methods sections (pages unavailable) describe stimulating cultured human cardiac fibroblasts with TGFβ1, supporting the TGFβ condition cited in the sentence. The paper does not compare cultured cardiac, dermal, and immortalized fibroblasts as models of human cardiac fibroblast diversity. Its Discussion instead says it is not yet known how well the cultured-cell transition reflects the trajectory inferred from single-nucleus data. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF.

    “While numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF 20,33”

    From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [20]

    The Cardiac fibrosis assay section (page unavailable) reports that TGFβ1 stimulated cardiac fibroblasts to become myofibroblasts and that disrupting TGFβ-signaling genes reduced this response. This supports a role in a fibrosis-related process, but the paper does not establish that TGFβ signaling causes maladaptive remodeling or scar formation in heart failure, nor does it substantiate the claim about numerous studies. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Numerous single-nucleus RNA sequencing studies have investigated the healthy and failing human heart.

    “Numerous single-nucleus RNA sequencing (snRNA-seq) studies have investigated the healthy and failing human heart18–22.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chaffin, M., Papangeli, I., Simonson, B., Akkad, A.-D., Hill, M. C., Arduini, A., Fleming, S. J., Melanson, M., Hayat, S., Kost-Alimova, M., Atwa, O., Ye, J., Bedi, K. C., Nahrendorf, M., Kaushik, V. K., Stegmann, C. M., Margulies, K. B., Tucker, N. R., & Ellinor, P. T.
Affiliations
  • Broad Institute (US)
  • University of Pennsylvania (US)
  • Massachusetts General Hospital (US)
  • Masonic Medical Research Laboratory (US)
Corresponding author
Ellinor, Patrick T.
Venue
Nature
Published
2022-06-22
Volume
608
Issue
7921
Pages
174-180
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4283257569
Cited by
418
References
61
Citations by year
2026: 110 · 2025: 120 · 2024: 100 · 2023: 67 · 2022: 19 · 2021: 1 · 2019: 1
FWCI
54.31
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • American Heart Association
  • National Institutes of Health (1s10od026839-01)
  • National Heart, Lung, and Blood Institute (K01HL140187, R01HL128914, R01HL105993, K24HL105780, R01HL092577, T32HL007208)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords
dilated cardiomyopathy, hypertrophic cardiomyopathy, heart failure, single-nucleus RNA sequencing, cardiac fibroblasts, myofibroblast differentiation, myocardial fibrosis, TGF-β1 signaling, CRISPR knockout screen, cardiac transcriptome, left ventricle, biomarkers, therapeutic target
MeSH terms
RNA-Seq, Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Cell Nucleus, Cells, Cultured, Heart Failure, Heart Ventricles, Humans, Myocardium, Transcription, Genetic, Case-Control Studies, Gene Expression Profiling, Transforming Growth Factor beta1, Gene Knockout Techniques, Myofibroblasts, Single-Cell Analysis, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review